Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
In the latest session, Elanco Animal Health Inc (NYSE: ELAN) closed at $22.38 up 0.72% from its previous closing price of $22.22. In other words, the price has increased by $0.72 from its previous closing price. On the day, 2.79 million shares were traded. ELAN stock price reached its highest trading level at $22.47 during the session, while it also had its lowest trading level at $22.1.
Ratios:
For a deeper understanding of Elanco Animal Health Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 22.02 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 30.22. For the most recent quarter (mrq), Quick Ratio is recorded 1.23 and its Current Ratio is at 2.40. In the meantime, Its Debt-to-Equity ratio is 0.60 whereas as Long-Term Debt/Eq ratio is at 0.59.
Upgrades & Downgrades
In the most recent recommendation for this company, Barclays on December 09, 2025, initiated with a Overweight rating and assigned the stock a target price of $30.
On November 21, 2025, KeyBanc Capital Markets started tracking the stock assigning a Overweight rating and target price of $27.
Argus Upgraded its Hold to Buy on November 19, 2025, while the target price for the stock was maintained at $25.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 12 ’25 when Kurzius Lawrence Erik bought 10,000 shares for $21.30 per share. The transaction valued at 213,000 led to the insider holds 131,773 shares of the business.
Modi Rajeev A. bought 4,500 shares of ELAN for $95,985 on Dec 11 ’25. The insider now owns 123,082 shares after completing the transaction at $21.33 per share. On Dec 11 ’25, another insider, VanHimbergen Robert M, who serves as the EVP and CFO of the company, bought 6,950 shares for $21.64 each. As a result, the insider paid 150,426 and bolstered with 124,233 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ELAN now has a Market Capitalization of 11119804416 and an Enterprise Value of 14938804224. As of this moment, Elanco’s Price-to-Earnings (P/E) ratio for their current fiscal year is 307.00, and their Forward P/E ratio for the next fiscal year is 21.71. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.69. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.42 while its Price-to-Book (P/B) ratio in mrq is 1.65. Its current Enterprise Value per Revenue stands at 3.254 whereas that against EBITDA is 16.937.
Stock Price History:
The Beta on a monthly basis for ELAN is 1.87, which has changed by 0.85572135 over the last 52 weeks, in comparison to a change of 0.16098404 over the same period for the S&P500. Over the past 52 weeks, ELAN has reached a high of $23.70, while it has fallen to a 52-week low of $8.02. The 50-Day Moving Average of the stock is 1.84%, while the 200-Day Moving Average is calculated to be 37.85%.
Shares Statistics:
For the past three months, ELAN has traded an average of 5.61M shares per day and 6599900 over the past ten days. A total of 496.83M shares are outstanding, with a floating share count of 492.22M. Insiders hold about 0.93% of the company’s shares, while institutions hold 115.69% stake in the company. Shares short for ELAN as of 1765756800 were 20779472 with a Short Ratio of 3.70, compared to 1763078400 on 22453561. Therefore, it implies a Short% of Shares Outstanding of 20779472 and a Short% of Float of 5.7800002.
Earnings Estimates
The performance of Elanco Animal Health Inc (ELAN) in the stock market is under the watchful eye of 12.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is $0.35, with high estimates of $0.38 and low estimates of $0.3.
Analysts are recommending an EPS of between $1.05 and $0.92 for the fiscal current year, implying an average EPS of $0.94. EPS for the following year is $1.04, with 15.0 analysts recommending between $1.11 and $0.99.
Revenue Estimates
A total of 10 analysts believe the company’s revenue will be $1.09B this quarter.It ranges from a high estimate of $1.11B to a low estimate of $1.08B. As of. The current estimate, Elanco Animal Health Inc’s year-ago sales were $1.02BFor the next quarter, 10 analysts are estimating revenue of $1.28B. There is a high estimate of $1.3B for the next quarter, whereas the lowest estimate is $1.25B.
A total of 12 analysts have provided revenue estimates for ELAN’s current fiscal year. The highest revenue estimate was $4.73B, while the lowest revenue estimate was $4.65B, resulting in an average revenue estimate of $4.67B. In the same quarter a year ago, actual revenue was $4.44BBased on 12 analysts’ estimates, the company’s revenue will be $4.93B in the next fiscal year. The high estimate is $5.01B and the low estimate is $4.87B.
